Taysha Gene Therapies Inc (TSHA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $5.01 (-2.91%), Market cap $1.82B, 52-week low–high $1.90 ~ $6.72.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license
Financial statements, price targets, institutional (13F) holdings and related news for Taysha Gene Therapies Inc are updated in real time on BlackAll Trade.
Taysha Gene Therapies Inc trades at $5.01 (-2.91%). Real-time quotes and charts are available on BlackAll Trade.
Taysha Gene Therapies Inc has a market cap of about $1.82B.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic disease